摘要:
The invention describes a novel pharmaceutical preparation for treating IRDS or ALI, comprising at least one modification of surfactant protein B (SP-B) and at least one modification of surfactant protein C (SP-C).
摘要:
The invention concerns a process for the production of a powdered pulmonary surfactant preparation containing a hydrophobic protein serving as a pulmonary surfactant characterized by the fact that an organic solution or suspension containing a hydrophobic protein serving as a pulmonary surfactant and possibly other components is subject to spray drying. Powder preparations are obtained that exhibit very good stability under storage, are easy to reconstitute and which are also suitable for administration by inhalation.
摘要:
Dihydropyridine de formule (I) dans laquelle R6 et R7 représentent conjointement, et y compris l'atome d'azote auquel ils sont tous deux liés, un résidu de formule (II), dans laquelle A est -CH2-C(R8)R9-CH2-; R8 est aryle et R9 est aryle, aryle représentant un composé cyclique de formule (III) dans laquelle R10 et R11 sont identiques ou différents et sont hydrogène, alkyle, alkoxy, halogène, hydroxy ou trifluorométhyle, et où soit E est alkylène, R2 amino et R3 alkyle ou alkoxyalkyle, soit E est A1-0-A2, R2 est hydrogène, alkyle ou alkoxyalkyle et R3 est hydrogène, alkyle ou alkoxyalkyle, A1 étant alkylène et A2 étant alkylène ou alkylèneoxy-alkylène. Sont également décrits les sels de ces composés, ainsi qu'un procédé pour leur production et leur utilisation comme médicaments.
摘要:
The invention describes a set for the treatment of IRDS, ALI or ARDS, comprising a first container which has a volume of 50 to 500 ml and contains a pulverulent pulmonary surfactant preparation, the amount of phospholipids in the container being 50 to 500 mg, and a second container which has a volume of 50 to 500 ml and contains a pulverulent pulmonary surfactant preparation, where the amount of phospholipids in the second container is 1 to 10 g.
摘要:
Novel compositions for the treatment of IRDS and ARDS are indicated which contain a compound of formula (I), in which R1 is hydrogen or 2-(2-hydroxyethoxy)ethyl and/or a pharmacologically tolerable salt of this compound and lung surfactant.
摘要:
Des dihydropyridines énantiomériquement pures de formule (I), dans laquelle les substituants et les symboles ont les notations indiquées dans la description, sont de nouveaux composés présentant des propriétés pharmacologiques étonnantes. Un nouveau procédé pour fabriquer ces composés est décrit.
摘要:
Utilisation d'acides carboxyliques d'oxirane de formule (I), dans laquelle R1, R2, R3, Y et n ont les significations indiquées dans les revendications, pour la prévention et/ou le traitement d'infections associées à une concentration accrue de cholesterol et/ou de triglyceride.
摘要:
Composition for the treatment of infant or adult respiratory distress syndrome (IRDS and ARDS) contains N-(3,5-dichloropyrid-4-yl)-3- cyclopropylmethoxy-4- difluoromethoxybenzamide (II) (and/or its salts) and a lung surfactant.
摘要:
The invention concerns a process for the production of a powdered pulmonary surfactant preparation containing a hydrophobic protein serving as a pulmonary surfactant characterized by the fact that an organic solution or suspension containing a hydrophobic protein serving as a pulmonary surfactant and possibly other components is subject to spray drying. Powder preparations are obtained that exhibit very good stability under storage, are easy to reconstitute and which are also suitable for administration by inhalation.
摘要:
Novel compositions are disclosed for the treatment of IRDS and ARDS, containing at least one glucocorticosteroid and a pulmonary surfactant. The duration of treatment and the mortality associated with these syndromes can be significantly reduced with the proposed novel compositions.